Franz-Josef Müller & Helene Kretzmer
Real-time cancer classification with nanopore sequencing
About Franz-Josef Müller & Helene Kretzmer
Franz-Josef Müller works clinically as a Neuropsychiatrist at the University Hospital Schleswig-Holstein in Germany. His research interest is in combining cutting-edge molecular and cell biology tools with bioinformatics methods to develop clinically actionable assays. Previously, he headed the development of predictive assays for stem cell research (www.pluritest.org), and he has worked with Oxford Nanopore Technologies on Cas9-based enrichment and analysis strategies for neuropsychiatric disorders.
Helene Kretzmer heads the bioinformatics group at the Department for Genome Regulation at the Max Planck Institute for Molecular Genetics in Berlin, Germany. She has developed methods for DNA methylation sequencing analysis and their application to cancer data. Her current research focuses on utilizing single-cell RNA and whole-genome methylation sequencing to study epigenetic factors regulating early mammalian embryonic development, and understanding the epigenetic footprint of cancer.
Our presentation will discuss approaches towards utilizing DNA methylation obtained with nanopore sequencing in real-time for cancer classification. We suggest that nanopore sequencing could deliver a reliable molecular diagnosis of distinct malignant entities based on preliminary results. The development of robust machine learning models suitable for data streams offers the unique opportunity to obtain diagnostic information within the timeframe of an oncologic operation. We posit that such tools will enable — among other applications — intraoperative sequencing for the diagnosis of brain tumors in neuro-oncology.